Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Chino F, Kamal A, Chino J. Incidence of Opioid-Associated Deaths in Cancer Survivors in the United States, 2006-2016: A Population Study of the Opioid Epidemic. JAMA Oncol. 2020;6(7):1100–1102. doi:10.1001/jamaoncol.2020.0799
More than 40 000 people in the US died owing to opioids in 2016; the epidemic tops public health concerns. Opioids are commonly used for cancer-associated pain, and there has been a call for oncologists to become more aware of opioid-related risks and benefits.1 It is unknown, however, if opioid-related deaths in cancer survivors are rising at the same rate as in the general population.
Death certificate data were obtained from the National Center for Health Statistics (NCHS). Death certificates contain 1 underlying cause of death, up to 20 contributing causes, and demographic data. All deaths owing to opioids were included from 2006 through 2016; if present, cancer was noted as a contributing cause. Opioid-related death incidence was calculated from the US population and estimated cancer survivor population,2 both via NCHS data. To assess for differences, χ2 and R2 tests were used. Statistical significance was defined as α < .05 on a 2-sided significance level. All statistical analyses were performed with SPSS, version 21 (IBM). The Duke University Medical Center Institutional Review Board provided a waiver (Pro00045337) for this study, given that it is publicly available deidentified data. Informed consent is waived for publicly available, deidentified databases. Data were collected from May through August 2018, and analysis was completed in September 2019.
Create a personal account or sign in to: